Century Therapeutics, INC 10-Q quarterly reports

Century Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in its iPSC cell therapy platform, significant operating losses, and a substantial cash position sufficient into early 2029.

Century Therapeutics reports a significant drop in collaboration revenue and continued operating losses in its Q1 2026 filing, while highlighting progress in its iPSC cell therapy pipeline.

Century Therapeutics reports a nine-month net income driven by a collaboration termination, extends its cash runway into Q4 2027, and reprioritizes its cell therapy pipeline.

Century Therapeutics reported a significant net income increase driven by a collaboration termination, while discontinuing a key lymphoma program and implementing a 51% workforce reduction to prioritize autoimmune and preclinical programs.

Century Therapeutics' Q1 2025 results show a significant net income increase due to the termination of the Bristol-Myers Squibb collaboration agreement.

Century Therapeutics reports its third quarter 2024 financial results, detailing progress in clinical trials, strategic pipeline expansion, and a strengthened financial position.

Century Therapeutics reported its second quarter 2024 financial results, highlighting progress in clinical trials and strategic acquisitions.

Century Therapeutics reported a net loss of $28.1 million for the first quarter of 2024, while highlighting progress in clinical trials and strategic acquisitions.